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Abstract
Background and objective: Despite the high mortality and morbidity associated with abnormalities in mineral and bone me-
tabolism in haemodialysis patients, there is limited data on the pattern of  mineral bone disorder in African CKD population. 
Therefore, the purpose of  this study was to describe the pattern of  mineral bone disease by evaluating biochemical parameters 
in patients on maintenance haemodialysis (MHD).
Methods:  We evaluated the serum/plasma intact parathyroid hormone (iPTH), corrected calcium, phosphate, total alkaline 
phosphatase (TALP) and 25 –OH vitamin D levels of  two hundred and seven patients undergoing MHD at two dialysis centers 
in Johannesburg.
Results: The MHD patients (133 men, 74 women) had a mean age of  54.5±15.6 years with a median dialysis vintage of  24 
months (IQR, 12-48) and a mean kt/V of  1.45±0.28. The prevalence of  hyperparathyroidism (iPTH >150 pg/ml), hyperphos-
phataemia, hypocalcaemia and 25-OH vitamin D deficiency (<30 ng/ml) was 73.4%, 57.0%, 20.3% and 80.7 % respectively. The 
combination of  markers of  bone turnover (iPTH >150pg/ml and TALP> 112 U/L) suggestive of  high turnover bone disease, 
was present in 47.3 % of  the study population. In multiple-logistic regression analysis, the odds ratio for developing hyperpara-
thyroidism with hypocalcaemia and hyperphosphataemia were 5.32 (95% CI 1.10 - 25.9, P = 0.03) and 3.06(95 % CI 1.15 - 8.10, 
P=0.02) respectively.  Ninety eight (47.3%) of  the MHD patients had iPTH within the recommended kidney disease improving 
global outcome (KDIGO) guidelines.
Conclusion: Secondary hyperparathyroidism and 25–OH vitamin D deficiency were common in our haemodialysis patients. 
Hypocalcaemia and hyperphosphataemia were strong predictors for developing secondary hyperparathyroidism.
Keywords: Biochemical markers, guidelines, mineral bone disorder, haemodialysis.
DOI: https://dx.doi.org/10.4314/ahs.v17i2.19
Cite as: Bala W, Raquel D, Saraladevi N. Biochemical markers of  mineral bone disorder in South African patients on maintenance haemodialysis. 
Afri Health Sci. 2017;17(2): 445-452. https://dx.doi.org/10.4314/ahs.v17i2.19
Corresponding author: 
Waziri Bala,
Department of  Internal Medicine, 
Faculty of  Health Sciences, 





Chronic kidney disease-mineral bone disorder (CKD 
MBD) is now defined as a systemic disorder of  mineral 
and bone metabolism due to CKD manifested by either 
one or a combination of  the following: (i) abnormalities 
of  calcium, phosphorus, parathyroid hormone (PTH), or 
vitamin D metabolism; (ii) abnormalities in bone turn-
over, mineralization, volume, linear growth, or strength; 
or (iii) vascular or other soft tissue calcification and  that 
the term renal osteodystrophy should exclusively be used 
to describe disorders in bone morphology associated 
with CKD1,2.  Although bone biopsy is the gold standard 
for adequately describing the spectrum of  CKD- MBD, 
it is less frequently utilized in clinical settings because 
of  associated constraints. It is an invasive and cumber-
some procedure that requires highly skilled personnel to 
interpret the obtained tissue samples. Therefore, clini-
cians largely depend on the biochemical parameters for 
monitoring and management of  this important clinical 
entity that is associated with adverse clinical outcomes in 
CKD patients. In addition, the above aforementioned in-
ternationally acceptable definition has led to the ease of  
diagnosing CKD MBD and allows valid comparison of  
studies in this field.
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In 2009, through extensive review of  the literature the 
KDIGO (Kidney Disease Improving Global Outcomes) 
guideline work group came up with guidelines to assist 
clinicians in the management of  patients with CKD–
MBD2. The guidelines were largely based on studies con-
ducted on Asian, European and American populations. 
These guidelines were adopted by many African coun-
tries despite existence of  racial differences in PTH, vita-
min D and phosphorus as demonstrated by several stud-
ies3-5. The lack of  use of  literature from Africa is likely 
due non-availability of  robust data from these regions. 
Therefore, information obtained from this present study 




Participants and study design
This was a cross-sectional descriptive study involving two 
hundred and seven patients undergoing MHD (from June 
2009 to April 2016) at two dialysis centers in Johannes-
burg, aged ≥ 18 years with complete data for analysis. Ex-
clusion criteria included patients with active malignancy, 
active liver disease, and patients on medications such as 
bisphosphonates or warfarin. Demographic and clinical 
data collected included age, gender, history of  medica-
tions, underlying aetiology of  CKD, duration of  haemo-
dialysis and blood pressure measurements. The research 
protocol was approved by the Health Research and Eth-
ics committee (HREC) of  the University of  the Witwa-
tersrand.
Laboratory measurements
Plasma intact PTH was measured by an electrochemi-
luminescence immunoassay (ECLIA) run on a Cobas 
6000auto analyzer (Roche Diagnostics, Mannheim, Ger-
many; reference range 10-65 pg/ml).
Serum 25-OH vitamin D was measured by a chemilumi-
nescent micro particle immunoassay (CMIA) technique 
(Abbott Laboratories, Abbott Park, Illinois, US). Refer-
ence ranges: < 10 ng/ml  as severe deficiency, 10-29 ng/
ml as  moderate deficiency, 30-100 ng/ ml as sufficiency 
and > 100 ng/ ml as toxic6.
Calcium, Phosphate and Alkaline phosphatase were 
measured using the ARCHITECT C8000 auto analyzer 
(Abbot Laboratories, Abbott Park, Illinois, US). Other 
biochemical parameters were determined using routine 
laboratory techniques.




Based on the above reference values and KDIGO rec-
ommendations the following definitions were employed 
in this study:
Hyperparathyroidism and hypoparathyroidism were de-
fined as intact PTH >150 pg/ml and PTH < 15 pg/ml 
respectively.
Hyperphosphataemia and hypophosphataemia were de-
fined as phosphate levels >1.45mmol/l and <0.80mmol/l 
respectively.
Hypercalcaemia and hypocalcaemia were defined as cal-
cium levels >2.50mmol/l and <2.12mmol/l respectively.
 
Statistical analysis.
Patients’ demographic and baseline characteristics were 
presented as means and standard deviations (SD) or me-
dians (Interquartile ranges) depending on the distribution 
of  the variable, while categorical data was presented as 
proportions or percentages. The means of  biochemical 
parameters were compared between diabetic and non-di-
abetic patients using an independent t – test and Pearson’s 
or Fisher’s exact test was utilized for proportion compar-
isons. Associations between log transformed PTH and 
other biochemical parameters were assessed by multiple 
linear regression analyses following significant associa-
tions obtained from univariate regression analyses. A lo-
gistic regression model was used to evaluate the effect of  
other biochemical parameters on the odds of  develop-
ing hyperparathyroidism. A p-value of  less than 0.05 was 
considered statistically significant at the 95% confidence 
interval. All analyses were performed using STATA ver-
sion 12 (STATA Corp., TX, and USA).
Results
Two hundred and seven MHD patients (133 men, 74 
women) were enrolled. Their mean age was 54.5±15.6 
years with a median dialysis vintage of  24 months (IQR, 
12-48) and a mean Kt/V of  1.45±0.28.  Fifty six (27.1%) 
of  the study population were diabetic. Medications re-
ceived included calcium carbonate 154 (74.4%), Alfacalci-
dol 132 (63.8%), Cholecalciferol 45(21.7%) and 12(5.8%) 
were on cinacalcet (Table 1). The majority of  patients 
were on three times weekly 4 hr sessions of  haemodial-
ysis.
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Table 2 shows a comparison of  biochemical parameters 
and distribution of  CKD-MBD abnormalities between 
diabetic (n=56) and non-diabetic (n=151) patients. Di-
abetic patients had significantly lower mean 25-OH vi-
tamin D as compared to non-diabetic patients. Other 
biochemical parameters were comparable between the 
groups.
The overall prevalence of  hyperparathyroidism (>150pg/
ml), hyperphosphataemia, hypocalcaemia and 25-OH vi-
tamin D deficiency(<30 ng/ml) was 73.4%, 57.0%, 20.3% 
and 80.7 % respectively. The combination of  markers of  
bone turnover (>150pg/ml and TALP> 112 IU/L) sug-
gestive of  high turnover bone disease, was present in 47.3 
% of  the study population (Table 2). 
Table1. Study population characteristics. 
Parameters Results 
Age(years) 54.5± 15.6 
Gender, n (%)   
Male 133(64.23%) 
Female 74(35.75%) 
Diabetes, n (%) 56(27.1%) 
Race, n (%)   
Black 121(58.5%) 
Non Black 86(41.5%) 
Creatinine(µmmol/l) 695.48± 278.61 
Calcium(mmol/l) 2.28±0.22 
Phosphate(mmo/l) 1.59±0.56 
Intact PTH(pg/ ml) 451.85±430.38 
25-OH vitamin D(ng/ml) 21.16±10.71 
Haemoglobin(g/dl) 10.26± 2.0 
Albumin(g/L) 31.91± 6.12 
Systolic BP(mmhg) 134.18±21.81 
Diastolic BP(mmhg) 72.03±13.74 
Alkaline phosphatase(UI/L) 143.21± 115.26 
Kt/V 1.45±0.28 
Dialysate Calcium (mmol/L)  1.72±0.09 
Dialysis vintage(months) 24(12-48) 
Calcium carbonate use n(%) 154(74.4%) 
Cinacalcet n (%) 12(5.8%) 
Alfacalcidol n (%) 132(63.8%) 
Cholecalciferol n (%)   45(21.7%) 
Continuous variables are presentedas mean± standard deviation and categorical data as frequencies (percentages). BP= blood pressure 
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Patients within KDIGO-recommended targets for calci- um, phosphate and PTH were 63.8%, 37.7 %, and 47.3% 
respectively (Table 3).
Table 2: Comparison of parameters/distribution of mineral bone disorder between diabetic and 
non-diabetic patients 
Variables ALL(N=207) DM(n=56) Non DM(n=151) P 
Intact PTH 451.85±430.38 439.05±489.51 454.70±413.05 0.83 
 Corrected Calcium(mmol/l) 2.28±0.22 2.30±0.21 2.275±0.22 0.41 
Phosphate(mmol/l) 1.59±0.56 1.52±0.51 1.61±0.58 0.25 
Alkaline phosphatase(IU/L) 143.21± 115.26 155.77±131.72 139.15±109.41 0.41 
Hyperparathyroidism (>150 pg/ml) 152(73.4%) 38(67.9%) 114(75.5%) 0.84 
Hypoparathyroidism (<10 pg/ml) 2(9.7%) 1(1.79%) 1(6.6%) 0.44 
Hyperphosphataemia(>1.45mmol/l) 118(57.0%) 27(48.2%) 91(60.3%) 0.19 
Hypophosphataemia(<0.80mmol/l) 11(5.3%) 4(7.1%) 7(4.6%) 0.44 
Hypercalcaemia(>2.50mmol/l) 26(12.6%) 8(14.3%) 18(11.9%) 0.53 
Hypocalcaemia(<2.12mmol/l) 42(20.3%) 10(17.9%) 32(21.2%) 0.91 
ALP (>112IU/L) 103(49.8%) 33(58.9%) 70(46.4%) 0.76 
25-Hydroxyvitamin D (N=161)         
25 OH vitamin D(ng/ml) 21.16±10.71 18.12±12.77 22.21±9.82 0.04 
(<30 ng/ml) 130(80.7%) 35(92.1%) 95(77.2%) 0.04 
(<15ng/ml) 47(29.2%) 16(42.1%) 31(25.2%) 0.03 
PTH>150&TALP>112 98(47.3%) 24(42.7%) 74(49.0%) 0.58 
Continuous variables are presented as mean± standard deviation and categorical data as frequencies (percentages). PTH= Parathyroidhormone, 
TALP= total alkaline phosphatase,     
Table 3. Distribution of patients achieving recommended guideline targets 
Guidelines Below target Within target Above target 
KDIGO       
PTH(2-9× upper normal range ) 44(21.3%) 98(47.3%) 65(31.4%) 
Calcium(within normal range) 48(23.1) 132(63.8%) 27(13.0%) 
Phosphate(within normal range) 11(5.3%) 78(37.7%) 118(57.0%) 
  
NKF KDOQI 
      
PTH(150-300 pg/ml) 51(24.6%) 54(26.1%) 102(49.3%) 
 Corrected calcium(8.9-9.5 mg/d L) 32(14.5%) 112(54.1%) 63(30.4%) 
Phosphate(3.5-5.5mg/dl)) 35(16.9%) 104(50.2%) 65(31.4%) 
         KDIGO, Kidney Disease Improving Global Outcomes; NKF KDOQI, National Kidney Foundation Kidney Disease Outcome Quality Initiative. 
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In multiple logistic regression analysis, hypocalcaemia and hyperphosphatasemia were identified as predictors 
of  hyper-parathyroidism (p<0.05) (Table 4).
Table 4. Logistic regression analysis for predictors of hyperparathyroidism. 
Variables Odds ratio 95 CI P-values 
Phosphate 3.06 1.15-8.10 0.024 
Calcium 5.32 1.10-25.9 0.03 
Alkaline phosphatise 1.67 0.66-4.29 0.28 
Diabetesmellitus 0.60 0.19-1.84 0.37 
Age 0.76 0.25-2.33 0.64 
25-hydroxyvitamin D 0.39 0.10-1.60 0.20 
 
CI, confidence interval; covariates were by categories, Age≥ 65 years versus<65 years, phosphate >1.45 mmol/l versus≤1.45mmol/l, calcium<2.12mmol/l 
versus≥2.12mmol/l, Alkaline phosphatase>112 UI/L versus ≤112 UI/L, 25-OH vitamin D <30ng/ml versus≥ 30ng/ml, Diabetes mellitus versus No diabetes. 
  
Univariate linear regression revealed a significant asso-
ciation between log transformed PTH and phosphate 
(r2=0.03, p=0.007),calcium (r2=0.02,p=0.03), total alka-
line phosphatase(r2=0.05,p=0.006), 25 –OH vitamin D 
(r2=0.05,p=0.005). When including all these parameters 
in a multiple regression analysis, only phosphate and 25-
OH vitamin D remained significantly correlated with log 
PTH; p= 0.02 and 0.04 respectively.
 
Discussion
In agreement with previous studies from Africa and de-
veloped countries7-9, this study has revealed a high prev-
alence of  derangements of  biochemical markers of  min-
eral bone disorder. Based on the cut-off  values utilized by 
this study, hyperparathyroidism (PTH>150) was present 
in 73.4% of  the patients and 37% with a stricter cut-off  
value of  585 ng/ml(9 times the upper normal of  our lab-
oratory assay ). However, because of  the dynamic nature 
and complexity of  bone homeostasis, it is difficult to rely 
on one biochemical marker as a surrogate test of  bone 
formation10. Therefore, utilizing both PTH and TALP, 
though not as specific as bone specific alkaline phospha-
tase, almost half  of  our study population were identi-
fied as having high bone turn over. In addition, the 2009 
Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines recommended measurement of  TALP every 
12 months in CKD 4-5D2, and the additional cost in 
routinely  utilizing bone specific alkaline phosphatase to 
monitor the management of  CKD-MBD has not been 
justified.
Comparison of  epidemiological data on prevalence of  vi-
tamin D deficiency is being hampered by lack of  consen-
sus on how to define this deficiency. However, the widely 
accepted definition includes serum 25 (OH) vitamin D 
levels below 20 ng/ml while patients with 25 (OH) vi-
tamin D levels between 20 and 30 ng/ml are considered 
to be vitamin D insufficient6.  One of  the striking results 
of  our study was the high prevalence (80.7%, N=161) 
of  inadequate vitamin D status in our study population 
and of  which 29.2 % were severely vitamin D deficient 
(<15 ng/m/). These findings are consistent with previ-
ous cross-sectional studies in Americans11-13. In contrast 
to our finding regarding severe deficiency,  Jabbar et al14 
reported vitamin D deficiency  (<15ng/ml) in 90 % of  
the patients and attributed it  to the low vitamin D con-
tent in the  traditional(vegetarian) Indian diet. Diabetic 
patients had significantly lower mean levels of  25-OH vi-
tamin D and inadequate vitamin D compared to non-dia-
betic patients. This finding is in line with previous studies 
from Europe and Asia15,16 in which a high prevalence of  
vitamin D deficiency was demonstrated in > 90% of  the 
diabetic patients.  This remarkably high prevalence could 
have been due to proteinuria, which is more common in 
diabetic nephropathy and is associated with heavy urinary 
loss of  vitamin D binding protein, as proposed by previ-
ous studies16,17.  However, in general, factors that could 
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account for vitamin D deficiency in patients with CKD 
include reduced dietary intake, loss of  vitamin D bind-
ing protein in urine and increased levels of  FGF 23 in 
CKD16.
In an attempt to reduce the adverse clinical outcomes 
associated with CKD-MBD several guidelines were pro-
posed by various regional and global bodies2,18,19. Based 
on the recommended target ranges by the widely adopt-
ed KDIGO guidelines2, more than half  of  our study 
population had serum phosphate levels above the target 
level (Phosphate>1.45mmol/L). This is similar to other 
large observational multicenter studies[Dialysis outcomes 
and practice patterns (DOPPS I)20 and a study from It-
aly21 that both reported  serum phosphate of  >5.5mg/
dl (1.78mmol/L) in 51.6% of  the patients. Despite the 
advances in haemodialysis, with the invention of  more 
effective dialysis membranes and the use of  ultrapure di-
alysate, the removal of  phosphate is still inadequate. The 
conventional HD (3 times per week, 4 h session) removes 
approximately 2.3-2.6g/week compared to 4.5-4.9g by the 
nocturnal HD ( 8hrs/day)22. The majority of  our patients 
are on conventional HD with a very few of  them (9.2%) 
on nocturnal dialysis. Therefore, one of  the reasons that 
could have accounted for the high prevalence of  hyper-
phosphataemia is the ineffective removal of  phosphate 
by conventional haemodialysis. In addition, calcium car-
bonate which is used as phosphate binder in most of  our 
patients has lower phosphate binding capacity compared 
to non-calcium based phosphate binders. Other notable 
patient factors are the adherence to both medications and 
dietary restriction.
In this study, according to the KDIGO recommendation 
that PTH should be maintained between 2-9 times the 
upper limit of  normal range (i.e. 130-585 pg/ml), the 
proportion of  patients within the target guideline level 
was higher than that reported by previous studies7,20,23. 
Their reported lower values were likely due to utiliza-
tion of  KDOQI guidelines with narrower recommended 
ranges of  PTH (150-300pg/ml).
Interestingly, a significant percentage of  our patients 
had their corrected calcium within the KDIGO recom-
mended guidelines which is higher than the report from 
DOPPS II 42.5 %20. Re analyzing our data based on 
KDOQI the number still remains slightly higher (54.1%). 
Overall, the discrepancy between the current study and 
other previous studies may likely be due to differences in 
the use of  phosphate binders, dialysate calcium concen-
tration and dietary phosphate intake.
In keeping with previous studies24, logistic regression anal-
ysis revealed hypocalcaemia and hyperphosphateamia as 
predictors of  hyperparathyroidism. This further supports 
the classical role of  hyperphospataemia and hypocalcae-
mia in the pathogenesis of  CKD-MBD. In addition, we 
found phosphataemia to have remained closely related to 
log-transformed PTH in multivariate linear regression.
The strength of  our study is the larger sample size com-
pared to other previous studies from Africa7,9,25.
Limitations of  our study include:
Firstly, the lack of  bone biopsy to definitively describe the 
patterns of  MBD in our patients. However, studies have 
shown a good association between biochemical markers 
and histological findings26,27. Secondly, this was a cross 
-sectional study so we could not establish a temporal rela-
tionship between the biochemical markers and phosphate 
binders. Thus there is a need for a longitudinal study to 
assess this relationship. Nonetheless, findings from this 
study have provided us with important insights on the 
spectrum of  CKD-MBD in African MHD patients.
Conclusion
Abnormalities of  biochemical markers of  mineral bone 
disorder were common in our MHD patients and mod-
erately large proportion of  the patients were outside the 
KDIGO recommended target levels. However, due to 
the existence of  racial differences in PTH, vitamin D and 
phosphorus levels it is unclear whether these guidelines 
could be extrapolated to African MHD patients.  There-
fore, there is a need for large multicenter studies in Africa 
to support management of  CKD-MBD in African pa-
tients with CKD.
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